查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1922946

BETA-內醯胺類抗生素酶市場：按酵素類型、產品形式、原生動物、應用和最終用戶分類 - 全球預測 2026-2032

Enzymes for B-lactam Antibiotics Market by Enzyme Type, Product Form, Source Organism, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，BETA-內醯胺類抗生素酶市值將達到 2.1247 億美元，到 2026 年將成長至 2.3857 億美元，到 2032 年將達到 4.6782 億美元，複合年成長率為 11.93%。

關鍵市場統計數據
基準年 2025 2.1247億美元
預計年份：2026年 2.3857億美元
預測年份 2032 4.6782億美元
複合年成長率 (%) 11.93%

為酵素創新、製程整合和監管重點如何重塑BETA-內醯胺類抗生素生產價值鏈提供了一個清晰的背景框架。

酵素在BETA-內醯胺類抗生素的生命週期中發揮至關重要的作用，影響合成途徑、下游加工和雜質譜。酵素的發現、設計和固定化技術的進步正在重塑頭孢菌素和青黴素類抗生素的生產方式，與傳統化學合成相比，能夠實現更具選擇性的化學反應並降低對環境的影響。同時，日益嚴格的法規環境和對供應鏈穩健性的更高要求，迫使製藥企業和合約研發生產力機構（CDMO）重新評估其酵素的籌資策略，尤其是在重組生產和嚴格的品管對於滿足藥典標準至關重要的領域。

計算設計趨勢、日益嚴格的監管、永續性要求以及不斷演變的外包模式正在重塑BETA-內醯胺類抗生素生產的酶法策略。

受技術、監管和商業性因素的驅動，BETA-內醯胺類抗生素生產的酵素體係正經歷多項變革。首先，計算設計和定向進化技術的進步縮短了客製化生物催化劑的開發週期，加速了從發現到中試規模檢驗的轉化。這種轉變為企業內部酵素最佳化以及酵素開發商與製藥企業之間建立策略聯盟提供了更多機會，從而共同開發針對特定應用的解決方案。同時，固定化技術和連續製程的改進提高了酵素製劑的運作和可重複使用性，改變了生產設施計算其資本投資和營運成本的方式。

美國近期關稅政策變化對抗生素生產中酵素原料採購、在地化和供應商合作策略的累積影響。

美國關稅措施和貿易政策調整將持續到2025年，對BETA-內醯胺類抗生素生產所用酵素原料的採購、供應鏈設計和商業談判產生重大影響。不斷上漲的進口關稅和相關的合規成本增加了從特定地區採購的關鍵中間體、試劑和酵素製劑的總到岸成本，迫使下游生產商重新評估其供應商組合和合約條款。為此，採購部門正在重新評估其庫存策略，從即時採購轉向增加關鍵酶的安全庫存，同時在貿易關係更好的地區尋找替代供應商。

一個將酵素類別、應用終點、生產模式、來源地和最終用戶優先順序連結起來的多維細分框架，指南戰略選擇。

嚴謹的市場區隔觀點揭示了BETA-內醯胺類抗生素生產中酵素創新與商業性需求的交會點。依酵素類型分類，市場涵蓋BETA-內醯胺酶、頭孢菌素醯基轉移酶和青黴素G醯基轉移酶。 BETA-內醯胺酶再分為A類、C類和D類，其中A類包括SHV和TEM。頭孢菌素醯基轉移酶通常由銅綠假單胞菌和變異擬桿菌產生，而青黴素G醯基轉移酶則由枯草桿菌和大腸桿菌等微生物產生。這種酵素層面的細分至關重要，因為每種酵素類別和生產微生物都具有獨特的反應特性、雜質風險和監管文件要求，這些都會影響下游製程設計和品質保證活動。

區域優勢、監管差異和不斷變化的貿易流如何影響全球製藥生產基地的酵素採購、在地化決策和合作模式

區域趨勢對BETA-內醯胺類抗生素生產的酵素來源、法規遵循和商業模式有顯著影響。在美洲，一個融合了先進生物製藥研發能力和成熟製藥生產群集的生產生態系統已經形成，從而催生了對客製化重組酶和可擴展固定化系統的需求。監管以及與國內原料供應商的供應鏈整合進一步影響供應商的選擇和夥伴關係結構。同時，在歐洲、中東和非洲地區（EMEA），多樣化的管理體制和嚴格的永續性推動了人們對綠色化學的興趣，而成熟的生物技術和特種酵素生產能力則支持產研合作網路，加速了特定抗生素合成酶的最佳化。在亞太地區，快速的產能擴張、具有成本競爭力的生產方式以及大規模微生物發酵能力為微生物酶和重組酶提供了強大的供應基礎。然而，終端使用者必須應對不同司法管轄區內品質標準和不斷變化的監管要求。

透過專有的生物催化平台、合規的生產製造和一體化的開發服務，整合競爭優勢，以滿足製藥客戶的需求。

BETA-內醯胺酶領域的主要企業透過整合專有的生物催化平台、先進的固定化解決方案以及在頭孢菌素和青黴素化學領域的深厚應用經驗而脫穎而出。業界領導者投資於蛋白質工程、高通量篩檢和穩健的表達系統，以提供具有客製化動力學特性、在製程條件下具有更高穩定性以及更簡化的雜質譜的酶，從而簡化監管申報流程。同時，專業供應商提供將酵素供應與製程開發協助、分析方法轉移和放大支援相結合的綜合服務，從而加快客戶的生產速度並加強與供應商的長期合作關係。

制定可操作的跨產業優先事項，包括技術投資、供應商合作和供應鏈韌性，以加速酵素基生產並降低營運風險。

產業領導者應優先採取切實可行的措施，以充分利用技術進步並降低供應鏈和監管風險。首先，投資於模組化生產能力和重組表達平台，以實現靈活的規模化生產和酶批次的快速合格。這有助於降低對單一地區的依賴，並縮短對需求波動的反應時間。其次，在產品開發的早期階段就納入酵素的選擇標準，使製程科學家、法規事務和採購團隊能夠在開發生命週期的早期階段就酵素的規格、雜質容差和供應商選擇進行協作。這可以最大限度地減少下游返工，並加快監管申報流程。第三，透過共同開發契約深化與獎勵契約製造和酵素開發商的夥伴關係，旨在協調各方利益、共用風險並確保技術轉移的順利進行。

一項透明的調查方法結合了有針對性的初步訪談、技術案例研究和嚴​​謹的二手分析，以檢驗對相關人員的實際意義。

本分析所依據的研究結合了系統性的二手文獻綜述和有針對性的原始研究，以確保研究結果既有實證依據又具有實際應用價值。二手文獻綜述涵蓋了同行評審的科學文獻、專利申請、監管指導文件和上市公司披露資訊，旨在梳理技術趨勢、酶類別和領先的固定化技術。此外，我們也對製藥公司和契約製造製造商的研發總監、製程工程師、採購負責人和品管專業人員進行了結構化訪談和諮詢，以檢驗假設並識別在規模化生產和合格階段出現的實際限制。

簡要概述為什麼在酵素法抗生素生產中整合技術、監管和商業策略將決定哪些組織能夠獲得永續的優勢。

BETA-內醯胺類抗生素生產中酵素的應用軌跡取決於技術、監管和商業性因素的共同作用，這些因素有利於適應性強的生物催化劑、穩定的供應關係以及能夠最大限度減少環境影響的製程設計。蛋白質工程和固定化技術的進步正在創造顯著的營運優勢，但只有將酵素的選擇與監管規劃、供應商策略和生產系統設計相結合，才能真正實現這些創新的價值。貿易政策趨勢和區域能力進一步加劇了這一局面的複雜性，因此，戰略多元化和合約彈性是任何長期計劃的關鍵要素。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. BETA-內醯胺類抗生素酶市場（依酵素類型分類）

  • 青黴素醯化酶
    • 青黴素G醯化酶
    • 青黴素V醯化酶
  • 頭孢菌素醯基轉移酶
    • 頭孢菌素C醯化酶
    • 7-ACA醯化酶
  • 氨基青黴素醯化酶
    • 阿莫西林醯基轉移酶
    • Ampicillin醯化酶
  • 碳青黴烯類相關酶
    • Imipenem合成酶
    • Meropenem酶
  • 輔助酵素
    • 酯酶
    • 醯胺酶
    • BETA-內醯胺酶

9. BETA-內醯胺類抗生素酶市場（依產品形式分類）

  • 遊離酶
  • 固定化酵素
    • 吸附
    • 共用價鍵
    • 封裝
    • 已附上

10. BETA-內醯胺類抗生素用酵素市場（依來源分類）

  • 微生物來源
    • 細菌來源
      • 大腸桿菌
      • 芽孢桿菌
      • 鏈黴菌
    • 真菌
      • 麴菌
      • 青黴菌
  • 動物源性
    • 源自豬
    • 牛源
  • 植物來源
  • 重組/基因修飾
    • 基因工程改造的細菌宿主
    • 酵母宿主
    • 真菌宿主

11. 依應用分類的BETA-內醯胺類抗生素酶市場

  • 頭孢菌素合成
    • 頭孢羥氨芐
    • 頭孢氨芐
  • 青黴素合成
    • 青黴素G
    • 青黴素V

12. 依最終用戶分類的BETA-內醯胺類抗生素酶市場

  • 契約製造組織
  • 製藥公司

13. 各地區BETA-內醯胺類抗生素酶市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. BETA-內醯胺類抗生素酶市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國BETA-內醯胺類抗生素酶市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國BETA-內醯胺類抗生素酶市場

第17章 中國BETA-內醯胺類抗生素酶市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amicogen, Inc.
  • Aurobindo Pharma Limited
  • Biosynth AG
  • Centrient Pharmaceuticals Netherlands BV
  • Cipla Limited
  • Creative Enzymes, Inc.
  • Eucodis Bioscience GmbH
  • Fermenta Biotech Limited
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Limited
Product Code: MRR-867BED9A9E75

The Enzymes for B-lactam Antibiotics Market was valued at USD 212.47 million in 2025 and is projected to grow to USD 238.57 million in 2026, with a CAGR of 11.93%, reaching USD 467.82 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 212.47 million
Estimated Year [2026] USD 238.57 million
Forecast Year [2032] USD 467.82 million
CAGR (%) 11.93%

A clear contextual framing of how enzyme innovation, process integration, and regulatory priorities are redefining B-lactam antibiotic manufacturing value chains

Enzymes play an indispensable role in the life cycle of B-lactam antibiotics, influencing synthesis routes, downstream processing, and impurity profiles. Advances in enzyme discovery, engineering, and immobilization techniques have reshaped how cephalosporins and penicillins are manufactured, enabling more selective chemistries and reduced environmental footprints when compared with traditional chemical syntheses. In parallel, the regulatory environment and heightened scrutiny on supply chain robustness have pushed pharmaceutical manufacturers and contract development and manufacturing organizations to re-evaluate enzyme sourcing strategies, particularly where recombinant production and stringent quality control are essential to meet pharmacopeial standards.

Recent progress in protein engineering has accelerated the adaptation of enzymes to industrial conditions, improving thermostability, solvent tolerance, and substrate specificity, while process intensification and continuous manufacturing paradigms are creating new operational use cases for immobilized biocatalysts. Consequently, enzyme selection is no longer solely a biochemical decision but a cross-functional one that must incorporate considerations of scale-up, regulatory compliance, cost-to-serve, and strategic supplier relationships. This introduction sets the stage for a deeper examination of transformative shifts, regulatory and trade pressures, segmentation-driven opportunities, and region-specific dynamics that together define the current competitive landscape for enzymes applied to B-lactam antibiotic production.

How computational design, regulatory stringency, sustainability demands, and evolving outsourcing models are reshaping enzyme strategies across B-lactam antibiotic production

The landscape for enzymes in B-lactam antibiotic production is undergoing several transformative shifts driven by technological, regulatory, and commercial forces. First, advances in computational design and directed evolution are compressing development cycles for customized biocatalysts, enabling faster translation from discovery to pilot-scale validation. This shift is creating more opportunities for in-house enzyme optimization as well as strategic partnerships between enzyme developers and pharmaceutical manufacturers to co-develop application-specific solutions. At the same time, improvements in immobilization and continuous processing are increasing the operational lifespan and reusability of enzyme preparations, thereby altering capital utilization and operating expenditure calculations for production facilities.

Second, regulatory emphasis on product quality and supply chain transparency has incentivized investment in recombinant expression systems and traceable raw material sourcing. Consequently, organizations are prioritizing enzymes with robust characterization data, defined impurity profiles, and well-documented manufacturing controls. Third, sustainability and circularity imperatives are reshaping process design choices. The adoption of greener synthesis routes using enzymes reduces hazardous waste and energy consumption relative to classical chemical processes, making enzyme-enabled manufacturing a preferred option for companies seeking to meet corporate environmental targets and respond to stakeholder expectations. Finally, the maturation of contract manufacturing ecosystems that specialize in biocatalytic processes is creating new commercial models where pharmaceutical companies outsource complex enzymatic steps to specialist providers, thereby shifting the locus of investment and expertise within the value chain. Together, these changes are producing a dynamic environment where technological differentiation, regulatory alignment, and commercial partnerships determine competitive advantage.

The cumulative consequences of recent United States tariff shifts on procurement, localization, and supplier collaboration strategies for enzymatic inputs in antibiotic manufacturing

Tariff actions and trade policy adjustments in the United States through 2025 have had a meaningful effect on procurement, supply chain design, and commercial negotiations for enzymatic inputs used in B-lactam antibiotic manufacturing. Rising import duties and associated compliance costs have increased the total landed cost of key intermediates, reagents, and enzyme preparations sourced from certain jurisdictions, prompting downstream manufacturers to reassess supplier portfolios and contractual terms. In response, procurement teams have rebalanced inventory strategies, moving from just-in-time sourcing toward higher safety stocks for critical enzymes while simultaneously seeking alternative suppliers in jurisdictions with more favorable trade relationships.

Beyond immediate cost pressures, tariffs have catalyzed strategic shifts toward localization and dual-sourcing arrangements. Pharmaceutical firms and CMOs have accelerated investments in regional production capabilities and validated local supply chains to reduce exposure to tariff volatility and customs delays. This localization trend has also heightened the value of recombinant expression platforms and local biomanufacturing know-how, since domestic production of enzyme inputs can mitigate tariff impacts and improve responsiveness to regulatory inspections. Moreover, the increased transactional friction has amplified the importance of long-term supplier contracts and collaborative development agreements that embed risk-sharing mechanisms and price-stabilization clauses. In sum, the cumulative effect of tariff policies has been to increase strategic emphasis on supply resilience, foster nearshoring where feasible, and drive more integrated commercial relationships between enzyme developers, suppliers, and end users.

A multidimensional segmentation framework connecting enzyme classes, application endpoints, production formats, source origins, and end-user priorities to inform strategic choices

A rigorous segmentation-based perspective illuminates where enzyme innovation and commercial demand intersect within B-lactam antibiotic production. When considering enzyme type, the market encompasses beta-lactamase, cephalosporin acylase, and penicillin G acylase, with beta-lactamase further differentiated across Class A, Class C, and Class D, and Class A including SHV and TEM types, while cephalosporin acylase sources are exemplified by Pseudomonas aeruginosa and Variovorax paradoxus and penicillin G acylase is produced from organisms such as Bacillus subtilis and Escherichia coli. This enzyme-level granularity matters because each enzyme class and producer organism carries distinct kinetic properties, impurity risks, and regulatory documentation requirements that influence downstream process design and quality assurance activities.

Moving to application-based segmentation, demand is shaped by cephalosporin synthesis and penicillin synthesis, with cephalosporin routes targeting molecules like cefadroxil and cephalexin while penicillin pathways focus on penicillin G and penicillin V. These application endpoints dictate substrate specificities, reaction conditions, and purification strategies and therefore determine which enzyme types and production formats are most appropriate for a given manufacturing scenario. Considering product form, free enzymes and immobilized enzymes present different operational trade-offs; immobilized preparations rely on techniques such as adsorption, covalent bonding, encapsulation, and entrapment to enhance reusability and stability, while free enzymes may offer greater initial activity but shorter operational lifetimes. In terms of source, the choice between microbial and recombinant origins affects traceability, scalability, and regulatory dossiers. Finally, end-user segmentation between contract manufacturing organizations and pharmaceutical manufacturers reveals divergent procurement behaviors: CMOs emphasize process robustness and cost-per-batch optimization, whereas pharmaceutical companies may prioritize intellectual property protection, product-specific validation, and long-term supply certainty. Together, these segmentation axes provide a multidimensional framework to align enzyme selection, process development, and commercial engagement strategies with the specific technical and business requirements of different stakeholders.

How regional strengths, regulatory variation, and evolving trade flows shape enzyme sourcing, localization decisions, and collaborative models across global pharmaceutical production hubs

Regional dynamics exert a powerful influence on enzyme sourcing, regulatory compliance, and commercial models for B-lactam antibiotic manufacture. In the Americas, manufacturing ecosystems combine advanced biologics R&D capabilities with established pharmaceutical production clusters, creating demand for both customized recombinant enzymes and scalable immobilized systems; regulatory scrutiny and supply chain integration with domestic raw material suppliers further shape provider selection and partnership structures. Meanwhile, in Europe, Middle East & Africa, diverse regulatory regimes and strong sustainability mandates drive interest in green chemistry approaches, and established capacity in biotechnology and specialty enzyme production supports collaborative networks between academic centers and industry that help accelerate enzyme optimization for specific antibiotic syntheses. In the Asia-Pacific region, rapid capacity expansion, cost-competitive manufacturing, and large-scale microbial fermentation capabilities underpin a robust supply base for both microbial and recombinant enzymes, although end users must navigate heterogeneity in quality standards and evolving regulatory expectations across jurisdictions.

Transitional trade flows and regional policy differences influence decisions around localization, inventory strategy, and contractual structuring. For example, companies active across multiple regions frequently adopt hybrid sourcing strategies that combine local production in strategic markets with centralized high-value enzyme manufacturing to capitalize on technical expertise while reducing tariff and logistics exposure. Additionally, regional centers of excellence for immobilization technologies, protein engineering, and process intensification are enabling knowledge transfer across borders, thereby accelerating adoption of best practices and creating new commercial opportunities for value-added enzyme service providers. Overall, an appreciation of how regional strengths and constraints interact is essential to designing resilient enzyme supply chains and to aligning R&D investments with market opportunities.

A synthesis of competitive differentiation through proprietary biocatalyst platforms, regulatory-grade manufacturing, and integrated development services to meet pharmaceutical customer needs

Key companies in the enzyme-for-B-lactam space are differentiating through a combination of proprietary biocatalyst platforms, advanced immobilization solutions, and deep application know-how for cephalosporin and penicillin chemistries. Industry leaders are investing in protein engineering, high-throughput screening, and robust expression systems to deliver enzymes with tailored kinetics, improved stability under process conditions, and simplified impurity profiles that facilitate regulatory submissions. At the same time, specialist providers are creating integrated service offerings that combine enzyme supply with process development support, analytical method transfer, and scale-up assistance, thereby reducing time-to-production for customers and enhancing long-term supplier relationships.

Competitive strategies also emphasize strategic partnerships and co-development agreements with pharmaceutical companies and CMOs to align enzyme design with product-specific manufacturing requirements. Furthermore, value differentiation often arises from manufacturing footprint and quality systems: firms with validated recombinant production capabilities, certified quality management systems, and demonstrated regulatory inspection histories can command premium positioning when end users require confidence in supply and documentation. Technology providers that offer flexible product forms-ranging from high-activity free enzyme concentrates to immobilized formulations optimized for continuous reactors-are capturing demand from customers pursuing process intensification. In short, success in this sector depends on marrying technical excellence with service-oriented delivery models and regulatory-grade manufacturing practices.

Actionable, cross-functional priorities for technology investment, supplier collaboration, and supply chain resilience to accelerate enzyme-enabled production and reduce operational risk

Industry leaders should pursue a set of actionable priorities to capitalize on technological advances and to mitigate supply chain and regulatory risks. First, invest in modular production capabilities and recombinant expression platforms that enable flexible scaling and rapid qualification of enzyme lots; this reduces dependence on single geographies and shortens response times to demand fluctuations. Second, embed enzyme selection criteria into earlier stages of product development so that process scientists, regulatory affairs, and procurement collaborate on enzyme specifications, impurity expectations, and supplier qualification early in the development lifecycle. Doing so minimizes downstream rework and accelerates regulatory filings. Third, deepen partnerships with contract manufacturers and enzyme developers through co-development agreements that align incentives, share risk, and ensure technology transfer readiness.

Fourth, prioritize immobilization and continuous processing trials to evaluate total cost-of-ownership under anticipated production scenarios; early piloting can reveal throughput and durability advantages that translate into facility-level operational savings. Fifth, strengthen geographic diversification by establishing validated secondary supply sources or local production where tariff and trade policies create exposure, and incorporate contractual safeguards such as price-stabilization clauses and contingency supply commitments. Finally, augment technical investments with governance and quality frameworks that support traceability, batch-level documentation, and readiness for regulatory inspections. Together, these measures will enhance resilience, reduce time-to-market, and create competitive differentiation for organizations engaged in enzymatic B-lactam antibiotic production.

A transparent research approach combining targeted primary interviews, technical case studies, and rigorous secondary analysis to validate practical implications for stakeholders

The research underpinning this analysis combined systematic secondary review with targeted primary engagements to ensure findings are evidence-based and operationally relevant. Secondary analysis encompassed peer-reviewed scientific literature, patent filings, regulatory guidance documents, and public company disclosures to map technological trends, enzyme classes, and prevalent immobilization techniques. This foundation was augmented by structured interviews and consultations with R&D leaders, process engineers, procurement professionals, and quality experts across pharmaceutical companies and contract manufacturers to validate assumptions and surface practical constraints encountered during scale-up and qualification.

In addition, laboratory-level case studies and anonymized project retrospectives provided insight into performance trade-offs among free and immobilized enzyme formats, while comparative assessments of recombinant versus microbial sourcing clarified considerations around traceability and scalability. Data synthesis employed qualitative coding and triangulation to reconcile divergent viewpoints and to identify robust themes. Findings were reviewed by independent subject matter experts to ensure technical accuracy and commercial relevance. Throughout the research process, attention was paid to transparency of methodology, reproducibility of key observations, and the articulation of actionable implications for decision-makers.

A concise synthesis of why integrated technical, regulatory, and commercial strategies will determine which organizations capture durable advantages in enzyme-enabled antibiotic manufacturing

The trajectory of enzyme utilization in B-lactam antibiotic manufacturing is defined by converging technical, regulatory, and commercial forces that favor adaptable biocatalysts, robust supply relationships, and process designs that minimize environmental impact. Advances in protein engineering and immobilization technologies are creating compelling operational advantages, yet the full value of these innovations is realized only when enzyme selection is integrated with regulatory planning, supplier strategy, and manufacturing system design. Trade policy dynamics and regional capabilities further complicate the landscape, making strategic diversification and contractual resilience essential components of any long-term plan.

Looking ahead, organizations that couple technical investments with collaborative commercial models will be best positioned to turn enzyme-enabled process improvements into sustained competitive benefit. Embedding enzyme considerations early in product development, piloting immobilized continuous processes, and securing validated, geographically diversified supply chains will collectively reduce operational risk and unlock efficiency gains. In summary, the industry is at an inflection point where thoughtful alignment of science, operations, and commercial strategy will determine which players capture the next wave of improvements in B-lactam antibiotic production.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enzymes for B-lactam Antibiotics Market, by Enzyme Type

  • 8.1. Penicillin Acylases
    • 8.1.1. Penicillin G Acylase
    • 8.1.2. Penicillin V Acylase
  • 8.2. Cephalosporin Acylases
    • 8.2.1. Cephalosporin C Acylase
    • 8.2.2. 7-ACA Acylase
  • 8.3. Aminopenicillin Acylases
    • 8.3.1. Amoxicillin Acylase
    • 8.3.2. Ampicillin Acylase
  • 8.4. Carbapenem-related Enzymes
    • 8.4.1. Imipenem Synthesis Enzymes
    • 8.4.2. Meropenem Synthesis Enzymes
  • 8.5. Auxiliary Enzymes
    • 8.5.1. Esterases
    • 8.5.2. Amidases
    • 8.5.3. B-lactamases

9. Enzymes for B-lactam Antibiotics Market, by Product Form

  • 9.1. Free Enzyme
  • 9.2. Immobilized Enzyme
    • 9.2.1. Adsorption
    • 9.2.2. Covalent Bonding
    • 9.2.3. Encapsulation
    • 9.2.4. Entrapment

10. Enzymes for B-lactam Antibiotics Market, by Source Organism

  • 10.1. Microbial
    • 10.1.1. Bacterial
      • 10.1.1.1. Escherichia coli
      • 10.1.1.2. Bacillus Species
      • 10.1.1.3. Streptomyces Species
    • 10.1.2. Fungal
      • 10.1.2.1. Aspergillus Species
      • 10.1.2.2. Penicillium Species
  • 10.2. Animal
    • 10.2.1. Porcine
    • 10.2.2. Bovine
  • 10.3. Plant
  • 10.4. Recombinant / Engineered
    • 10.4.1. Genetically Modified Bacterial Hosts
    • 10.4.2. Yeast Hosts
    • 10.4.3. Fungal Hosts

11. Enzymes for B-lactam Antibiotics Market, by Application

  • 11.1. Cephalosporin Synthesis
    • 11.1.1. Cefadroxil
    • 11.1.2. Cephalexin
  • 11.2. Penicillin Synthesis
    • 11.2.1. Penicillin G
    • 11.2.2. Penicillin V

12. Enzymes for B-lactam Antibiotics Market, by End User

  • 12.1. Contract Manufacturing Organizations
  • 12.2. Pharmaceutical Manufacturers

13. Enzymes for B-lactam Antibiotics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Enzymes for B-lactam Antibiotics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Enzymes for B-lactam Antibiotics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Enzymes for B-lactam Antibiotics Market

17. China Enzymes for B-lactam Antibiotics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amicogen, Inc.
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Biosynth AG
  • 18.9. Centrient Pharmaceuticals Netherlands B.V.
  • 18.10. Cipla Limited
  • 18.11. Creative Enzymes, Inc.
  • 18.12. Eucodis Bioscience GmbH
  • 18.13. Fermenta Biotech Limited
  • 18.14. GlaxoSmithKline plc
  • 18.15. Hikma Pharmaceuticals PLC
  • 18.16. Lupin Limited
  • 18.17. Merck & Co., Inc.
  • 18.18. Merck KGaA
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Sanofi
  • 18.22. Sun Pharmaceutical Industries Limited
  • 18.23. Teva Pharmaceutical Industries Ltd.
  • 18.24. Wockhardt Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN C ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN C ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN C ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY 7-ACA ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY 7-ACA ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY 7-ACA ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMPICILLIN ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMPICILLIN ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMPICILLIN ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMIPENEM SYNTHESIS ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMIPENEM SYNTHESIS ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMIPENEM SYNTHESIS ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MEROPENEM SYNTHESIS ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MEROPENEM SYNTHESIS ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MEROPENEM SYNTHESIS ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESTERASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESTERASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESTERASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMIDASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMIDASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMIDASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY B-LACTAMASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY B-LACTAMASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY B-LACTAMASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FREE ENZYME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FREE ENZYME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FREE ENZYME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ADSORPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ADSORPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ADSORPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COVALENT BONDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COVALENT BONDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COVALENT BONDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENCAPSULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENCAPSULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENCAPSULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENTRAPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENTRAPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENTRAPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACILLUS SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACILLUS SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACILLUS SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY STREPTOMYCES SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY STREPTOMYCES SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY STREPTOMYCES SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIUM SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIUM SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIUM SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PORCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PORCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PORCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BOVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BOVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY GENETICALLY MODIFIED BACTERIAL HOSTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY GENETICALLY MODIFIED BACTERIAL HOSTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY GENETICALLY MODIFIED BACTERIAL HOSTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY YEAST HOSTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY YEAST HOSTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY YEAST HOSTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL HOSTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL HOSTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL HOSTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEFADROXIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEFADROXIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEFADROXIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALEXIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALEXIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALEXIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-20